Clinical Neuropathology, Volume 39 (2020) - July/August (188 - 195)

Predicting survival using the 2016 World Health Organization classification for anaplastic glioma
Je Beom Hong1, 9, Tae Hoon Roh3, Sung Soo Ahn5, Jung Youn Kim2, Seok-Gu Kang4, 6, 7, Jong Hee Chang4, 6, Se Hoon Kim6, 8
1 Department of Neurosurgery, 2 Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 3 Department of Neurosurgery, Ajou University Hospital, Ajou University School of Medicine, Suwon, 4 Department of Neurosurgery, 5 Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, 6 Brain Tumor Center, Severance Hospital, Yonsei University Health System, 7 Brain Research Institute, 8 Department of Pathology, Yonsei University College of Medicine, and 9 Graduate School, Yonsei University, Seoul, Republic of Korea

Add to Cart    

 

DOI 10.5414/NP301228

Abstract

Aim: This study aimed to investigate the survival and prognostic factors for anaplastic glioma, and whether the updated 2016 WHO classification had superior ability to predict survival.
Materials and methods: Between January 2001 and December 2013, 113 consecutive patients were diagnosed with anaplastic glioma based on the 2007 WHO classification. We re-classified their diagnoses in accordance with the 2016 WHO classification. The Kaplan-Meier method, multivariate Cox proportional regression analysis, and a time-dependent receiver operating characteristic curve were used for the analysis.
Results: The median overall survival was 48.4 months among all patients, and 21.5 months for the anaplastic astrocytoma, IDH wild-type (AAw) group. The median progression-free survival was 31.8 months among all patients and 16.4 in the AAw group. Age, MGMT promoter methylation status, deep tumor location, and resection extent were associated with overall survival and progression-free survival.
Conclusion: We found that the 2016 WHO classification of central nervous system tumors had superior ability to predict survival in cases of anaplastic glioma, as compared to the 2007 WHO classification.

Author Details

Authors

Departments

  • 1 Department of Neurosurgery,
  • 2 Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul,
  • 3 Department of Neurosurgery, Ajou University Hospital, Ajou University School of Medicine, Suwon,
  • 4 Department of Neurosurgery,
  • 5 Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine,
  • 6 Brain Tumor Center, Severance Hospital, Yonsei University Health System,
  • 7 Brain Research Institute,
  • 8 Department of Pathology, Yonsei University College of Medicine, and
  • 9 Graduate School, Yonsei University, Seoul, Republic of Korea

Address

Se Hoon Kim, MD, PhD
Department of Pathology
Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Republic of Korea
Email: [email protected]

Citation

Hong JB, Roh TH, Ahn SS, Kim JY, Kang S-G, Chang JH, Kim SH.Predicting survival using the 2016 World Health Organization classification for anaplastic glioma. Clin Neuropathol. 2020; 39: 188-195. doi: 10.5414/NP301228. Pubmed: https://pubmed.ncbi.nlm.nih.gov/32194024; PMID: 32194024.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart